KIM-1与循环肿瘤DNA为寡转移性透明细胞肾细胞癌的预后标志物:多变量预后模型的开发
本研究在评估转移导向治疗(MDT)寡转移性透明细胞肾细胞癌(ccRCC)的临床试验(NCT03575611)中检测血浆KIM-1浓度和循环肿瘤DNA(ctDNA)。基线、放疗结束时和3个月随访时的高KIM-1均与较短的系统治疗无进展生存期(STFS)相关;多变量分析显示KIM-1和ctDNA分子残留病状态在基线和3个月随访时均独立关联STFS;结合临床变量与基线KIM-1、ctDNA的K-COMPASS模型对STFS显示出良好的区分度(C指数0.76)和校准度。
要点
- 高KIM-1在基线、放疗结束和3个月随访均与较短STFS相关。
- 基线和3个月随访时KIM-1与ctDNA均独立关联STFS。
- K-COMPASS模型(临床变量+KIM-1+ctDNA)对STFS的C指数为0.76。
核心结论
- 血浆KIM-1和ctDNA在各时间点均独立与患者结局相关,加入临床变量后预后价值进一步提高。
研究设计与样本
- 在评估MDT用于寡转移性ccRCC的临床试验(NCT03575611)中测量血浆KIM-1浓度和ctDNA。
主要发现
- 较短STFS与基线高KIM-1相关(每log10 pg/ml的HR 2.45,95%CI 1.48-4.08;p<0.001)。
- 较短STFS与放疗结束时高KIM-1相关(HR 2.56,95%CI 1.56-4.21;p<0.001)。
- 较短STFS与3个月随访时高KIM-1相关(HR 3.22,95%CI 1.91-5.43;p<0.001)。
- KIM-1也与无进展生存期和总生存期相关。
- 多变量分析中,基线和3个月随访时KIM-1与ctDNA分子残留病状态均独立关联STFS。
关键数值与推荐
- 基线多变量分析:KIM-1 HR 1.91(95%CI 1.03-3.55;p=0.041),ctDNA HR 2.47(95%CI 1.08-5.64;p=0.03)。
- 3个月随访多变量分析:KIM-1 HR 2.22(95%CI 1.09-4.51;p=0.03),ctDNA HR 2.70(95%CI 1.09-6.67;p=0.03)。
- K-COMPASS模型包含四个临床变量加基线KIM-1和ctDNA,对STFS的C指数为0.76。
临床怎么用
- 血浆KIM-1和ctDNA可作为寡转移性ccRCC的预后标志物,辅助临床决策。
- K-COMPASS模型可用于预测STFS,帮助识别高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Better tools are needed for clinical decision-making in oligometastatic clear-cell renal cell carcinoma (ccRCC). Plasma KIM-1 concentrations and circulating tumor DNA (ctDNA) were measured in a clinical trial evaluating metastasis-directed therapy (MDT) for oligometastatic ccRCC (NCT03575611). Shorter systemic therapy-free survival (STFS) was associated with high KIM-1 at baseline (hazard ratio per log10 pg/ml [HR]: 2.45, 95% confidence interval [CI] 1.48-4.08; p < 0.001), the end of radiation therapy (HR 2.56, 95% CI 1.56-4.21; p < 0.001), and 3-mo follow-up (HR 3.22, 95% CI 1.91-5.43; p < 0.001). KIM-1 was also associated with progression-free survival and overall survival. In multivariable analysis, both KIM-1 and ctDNA molecular residual disease status were independently associated with STFS when measured at baseline (KIM-1: HR 1.91, 95% CI 1.03-3.55; p = 0.041; ctDNA: HR 2.47, 95% CI 1.08-5.64; p = 0.03) and 3-mo follow-up (KIM-1: HR 2.22, 95% CI 1.09-4.51; p = 0.03; ctDNA: HR 2.70, 95%CI 1.09-6.67; p = 0.03). After elastic net-informed selection, Weibull regression fitted with four clinical variables plus baseline KIM-1 and ctDNA yielded a prognostic model (K-COMPASS) for STFS that demonstrated favorable discrimination (C index 0.76) and calibration. In conclusion, plasma KIM-1 and ctDNA were independently associated with patient outcomes across time points, and their prognostic value further improved with the addition of clinical variables.
引用
- Tang C, Seo A, Sherry AD, et al. KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model. Eur Urol. 2026. PMID: 41765697. doi:10.1016/j.eururo.2026.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。